Liposomal antifungal agents workshop
FDA/National Institute of Allergy and Infectious Diseases workshop April 20 will focus on design of trials for liposome encapsulated drug products. The workshop will discuss "whether and how to conduct active-controlled trials of the liposomal drug... and whether the use of historical controls might be justified in some cases, and if so, how historical control data might be collected for specific fungal infections." The meeting will be held from 1 p.m. to 5 p.m. in conference room G of FDA's Parklawn building
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth